α-Synuclein-IN-20

α-Synuclein-IN-20 (compound 3ea) (30 μM; 72 h) potently inhibits the aggregation of purified human α-synuclein in vitro, with an AIR of 94.7%^[1].
α-Synuclein-IN-20 (0-100 μM) dose-dependently inhibits the aggregation of purified human α-synuclein, with an IC₅₀ of 4.1 μM, and exhibits strong activity at a concentration of 100 μM^[1].
α-Synuclein-IN-20 (30 μM; 72 h) stabilizes the random coil secondary structure of purified human α-synuclein monomers and inhibits the formation of β-sheet-rich aggregates^[1].
α-Synuclein-IN-20 (30 μM; 96 h) slows the aggregation kinetics of purified human α-synuclein, reducing the fiber growth rate constant to 0.271 h⁻¹. Its inhibitory effect is mainly achieved by reducing the formation of oligomeric nuclei during the lag phase^[1].
α-Synuclein-IN-20 (30 μM; 88 h) inhibits the formation of dense, cross-linked α-synuclein fibrils, and only produces short, sparse aggregates after incubation with purified human α-synuclein^[1].
α-Synuclein-IN-20 (30 μM; added at 21 h, 33 h, or 45 h, with total incubation up to 88 h) dissociates preformed purified human α-synuclein aggregates and inhibits their re-aggregation, with the highest potency when added during the aggregation lag phase^[1].
α-Synuclein-IN-20 (10 μM; 48 h post-transfection) significantly inhibits the formation of α-synuclein inclusions in human glioma H4 cells transfected with △155 and SNCAIP plasmids^[1].
α-Synuclein-IN-20 (3-10 μM; 30 min) scavenges reactive oxygen species (ROS) in human glioma H4 cells in a dose-dependent manner in vitro, with significant activity observed at the concentration of 10 μM^[1].
α-Synuclein-IN-20 (1-1000 μM; 24 h) exhibits low cytotoxicity in human glioma H4 cells and human neuroblastoma SH-SY5Y cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.